Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Patients With Definitely EGFR T790M State Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an EGFR TKI Agent

Trial Profile

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Patients With Definitely EGFR T790M State Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an EGFR TKI Agent

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Avitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Hangzhou ACEA Pharmaceutical Research
  • Most Recent Events

    • 29 Sep 2017 Planned number of patients changed from 172 to 294.
    • 29 Sep 2017 Planned End Date changed from 1 Feb 2018 to 1 Dec 2019.
    • 29 Sep 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top